Barcelona-based Aelix Therapeutics has appointed Dr Melanie Rolli as CEO. Her predecessor, Dr Jose Luis Cabero, had decided to step down from executive positions at Aelix
BD will build a €165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.
German government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.
AMSilk GmbH has closed a Series C financing at €29m to accelerate and expand commercialisation of its microbially produced silk fibres.
Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
International life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.
The Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
Topical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.
Belgium-based Celyad has had a new CMO since April: Dr Charles Morris.
Cell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.